Loading
A phase 2 trial of Ciltacabtagene autoleucel, Lenalidomide, Daratumumab in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma is a phase 2 interventional study registered as NCT04133636 by Janssen Research & Development, LLC, with 208 participants enrolled, started 2019-11-07 and due to reach its primary completion in 2027-02-26. Interventions recorded: JNJ-68284528, Lenalidomide, Daratumumab, Bortezomib, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ciltacabtagene autoleucel, Daratumumab, Bortezomib, Lenalidomide.
Shares Daratumumab, Lenalidomide, Dexamethasone, Johnson & Johnson.
Shares Ciltacabtagene autoleucel, Daratumumab, Bortezomib, Lenalidomide.
Shares Daratumumab, Bortezomib, Lenalidomide, Dexamethasone.
Shares Daratumumab, Bortezomib, Lenalidomide, Johnson & Johnson.
Shares Daratumumab, Bortezomib, Lenalidomide, Dexamethasone.
Shares Daratumumab, Lenalidomide, Johnson & Johnson, Multiple myeloma.
Shares Daratumumab, Lenalidomide, Dexamethasone, Johnson & Johnson.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/